Emerging drugs for urothelial (bladder) cancer

Kerwin Cumberbatch, Tianfang He, Zachary Thorogood, Benjamin A. Gartrell

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Metastatic urothelial carcinoma has been associated with poor prognosis and a median survival of approximately 12–14 months with standard therapy. Treatment options for decades have been limited to platinum based chemotherapy as first line with few therapeutic options available to the majority who will ultimately progress beyond platinum. Areas covered: This review focuses on the various targeted, antiangiogenic, chemotherapeutic and immunotherapeutic agents currently being developed for the treatment of urothelial carcinoma. Expert opinion: Incorporation of systemic immunotherapy into the treatment of urothelial carcinoma has already fundamentally changed the treatment of this disease. The landscape is rapidly changing and it is likely that immunotherapy will be incorporated into therapy in earlier disease states and in novel combinations. Outcomes in urothelial carcinoma have improved and likely to improve further with ongoing and future clinical research that is discussed in this review.

Original languageEnglish (US)
Pages (from-to)149-164
Number of pages16
JournalExpert Opinion on Emerging Drugs
Volume22
Issue number2
DOIs
StatePublished - Apr 3 2017

Fingerprint

Urinary Bladder Neoplasms
Pharmaceutical Preparations
Carcinoma
Platinum
Immunotherapy
Therapeutics
Expert Testimony
Drug Therapy
Research

Keywords

  • Bladder cancer
  • immune checkpoint
  • immunotherapy
  • molecular targets
  • targeted therapy
  • urothelial cancer (UC)

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging drugs for urothelial (bladder) cancer. / Cumberbatch, Kerwin; He, Tianfang; Thorogood, Zachary; Gartrell, Benjamin A.

In: Expert Opinion on Emerging Drugs, Vol. 22, No. 2, 03.04.2017, p. 149-164.

Research output: Contribution to journalReview article

Cumberbatch, Kerwin ; He, Tianfang ; Thorogood, Zachary ; Gartrell, Benjamin A. / Emerging drugs for urothelial (bladder) cancer. In: Expert Opinion on Emerging Drugs. 2017 ; Vol. 22, No. 2. pp. 149-164.
@article{247de3db73a84841bc4bf1bc3fd98daa,
title = "Emerging drugs for urothelial (bladder) cancer",
abstract = "Introduction: Metastatic urothelial carcinoma has been associated with poor prognosis and a median survival of approximately 12–14 months with standard therapy. Treatment options for decades have been limited to platinum based chemotherapy as first line with few therapeutic options available to the majority who will ultimately progress beyond platinum. Areas covered: This review focuses on the various targeted, antiangiogenic, chemotherapeutic and immunotherapeutic agents currently being developed for the treatment of urothelial carcinoma. Expert opinion: Incorporation of systemic immunotherapy into the treatment of urothelial carcinoma has already fundamentally changed the treatment of this disease. The landscape is rapidly changing and it is likely that immunotherapy will be incorporated into therapy in earlier disease states and in novel combinations. Outcomes in urothelial carcinoma have improved and likely to improve further with ongoing and future clinical research that is discussed in this review.",
keywords = "Bladder cancer, immune checkpoint, immunotherapy, molecular targets, targeted therapy, urothelial cancer (UC)",
author = "Kerwin Cumberbatch and Tianfang He and Zachary Thorogood and Gartrell, {Benjamin A.}",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/14728214.2017.1336536",
language = "English (US)",
volume = "22",
pages = "149--164",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Emerging drugs for urothelial (bladder) cancer

AU - Cumberbatch, Kerwin

AU - He, Tianfang

AU - Thorogood, Zachary

AU - Gartrell, Benjamin A.

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: Metastatic urothelial carcinoma has been associated with poor prognosis and a median survival of approximately 12–14 months with standard therapy. Treatment options for decades have been limited to platinum based chemotherapy as first line with few therapeutic options available to the majority who will ultimately progress beyond platinum. Areas covered: This review focuses on the various targeted, antiangiogenic, chemotherapeutic and immunotherapeutic agents currently being developed for the treatment of urothelial carcinoma. Expert opinion: Incorporation of systemic immunotherapy into the treatment of urothelial carcinoma has already fundamentally changed the treatment of this disease. The landscape is rapidly changing and it is likely that immunotherapy will be incorporated into therapy in earlier disease states and in novel combinations. Outcomes in urothelial carcinoma have improved and likely to improve further with ongoing and future clinical research that is discussed in this review.

AB - Introduction: Metastatic urothelial carcinoma has been associated with poor prognosis and a median survival of approximately 12–14 months with standard therapy. Treatment options for decades have been limited to platinum based chemotherapy as first line with few therapeutic options available to the majority who will ultimately progress beyond platinum. Areas covered: This review focuses on the various targeted, antiangiogenic, chemotherapeutic and immunotherapeutic agents currently being developed for the treatment of urothelial carcinoma. Expert opinion: Incorporation of systemic immunotherapy into the treatment of urothelial carcinoma has already fundamentally changed the treatment of this disease. The landscape is rapidly changing and it is likely that immunotherapy will be incorporated into therapy in earlier disease states and in novel combinations. Outcomes in urothelial carcinoma have improved and likely to improve further with ongoing and future clinical research that is discussed in this review.

KW - Bladder cancer

KW - immune checkpoint

KW - immunotherapy

KW - molecular targets

KW - targeted therapy

KW - urothelial cancer (UC)

UR - http://www.scopus.com/inward/record.url?scp=85021100987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021100987&partnerID=8YFLogxK

U2 - 10.1080/14728214.2017.1336536

DO - 10.1080/14728214.2017.1336536

M3 - Review article

VL - 22

SP - 149

EP - 164

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 2

ER -